Upfront Briefing
Risk appetite stayed switched on, but biotech's real story was stock-specific and mostly ugly: Roche finally shelved tominersen, Ionis and AstraZeneca whiffed in ATTR-CM, and GSK walked from its ~$2.2B Alector neuro pact — a reminder that binary science still settles the bill. The lone bright note was federal: ARPA-H earmarked $160M for custom gene editing. Translation: data risk giveth, policy cash taketh away a little less.
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
7,543.6 |
+0.8% |
+10.0% |
| Nasdaq 100 |
29,727.1 |
+1.6% |
+17.9% |
| Russell 2000 |
2,992.5 |
+1.2% |
+19.3% |
| Healthcare (XLV) |
162.2 |
(0.1%) |
+4.3% |
| Biotech (XBI) |
164.3 |
+0.8% |
+35.3% |
| Nasdaq Biotech (NBI) |
6,819.0 |
+0.4% |
+19.5% |
| Clinical Trials (BBC) |
54.9 |
+1.8% |
+45.8% |
|
- Biotech shrugged off a brutal neuro data day — Roche/Ionis's tominersen and Ionis/AstraZeneca's eplontersen both missed — with XBI still +0.8% and clinical-stage BBC leading at +1.8% as buyers stayed in earlier-stage beta over healthcare defensives (XLV (0.1%)).
- The broad tape rode a chipmaker rebound into SK Hynix's July 10 Nasdaq debut (reported ~7x oversubscribed), with Micron and SanDisk sharply higher; investors looked past renewed U.S.–Iran strikes as the 10Y eased ~2bps to ~4.55% and the VIX slid below 16.
- Market data: U.S. cash close Thursday, 9 July 2026.
The Big 3
|
1
|
Ionis, Roche hit by Huntington's and ATTR-CM setbacks
|
- Tominersen did no better than placebo in one Huntington's trial, while eplontersen from Ionis and AstraZeneca missed a Phase III ATTR-CM study.
- Why it matters: Two late-stage misses in Huntington's and ATTR-CM knock a chunk of risk-adjusted value out of both names and hand the ASO skeptics fresh ammunition — tominersen lowered mutant huntingtin without moving disease severity, the same efficacy gap that sank its Phase 3 predecessor. Eplontersen's ATTR-CM whiff caps upside in a cardiomyopathy franchise where Alnylam and BridgeBio already hold the momentum, though the approved polyneuropathy label (Wainua) is untouched. Roche is now reallocating neuro spend after burying two HD programs in one letter. IONS slipped on the read; watch the knock-on to other huntingtin- and TTR-lowering antisense assets.
- Source: Endpoints
- More: Fierce Biotech; BioCentury
|
|
2
|
GSK walks away from Alector's $2.2B neuro pact
|
- GSK is terminating its 2021 Alector alliance — $700M upfront, up to $1.5B in milestones — effective Jan. 2, 2027, after Phase 3 latozinemab (FTD) and Phase 2 nivisnebart (early Alzheimer's) both failed. ALEC fell ~13%.
- Why it matters: Two progranulin antibodies, two clinical dead ends — and GSK is out, stranding Alector with a preclinical pipeline and a balance sheet it just simplified by retiring a $10.4M Hercules loan. It's Alector's second big-pharma exit in 18 months after AbbVie dropped AL002 in 2025, and it hardens the read that progranulin elevation hasn't delivered functional benefit in neurodegeneration. GSK isn't retreating from external innovation — it bought Nuvalent for $10.6B in June — it's cutting a bet that stopped paying. ALEC (~$200M cap) now trades on the ABC blood-brain-barrier platform and cash, not a partnered late-stage asset.
- Source: Endpoints
- More: BioPharma Dive; BioSpace
|
| 3 | ARPA-H sets aside $160M for custom gene editing |
- $160M from ARPA-H is earmarked for custom gene editing treatments, backing bespoke development models in rare disease.
-
Why it matters:
Up to $160 million gives rare-disease gene-editing teams non-dilutive capital to build reusable platforms rather than one-off programs. The read-through is strongest for enabling players that can plug into umbrella-trial, common-CMC, and scalable-delivery models instead of bespoke single-asset economics — names like Prime Medicine, Beam, and the n-Lorem model. The catch: $160M spread across multiple awards is a policy signal more than a fundable runway, so the value here is validation — a federal stamp on platform-not-product — more than the dollars.
-
Source:
ARPA-H
|
Everything Else that broke
- Fate's off-the-shelf iPSC CAR-T (FT819) improved skin scores in 4 treatment-resistant systemic sclerosis patients within ~3 months, with no CRS, ICANS, or GvHD, in an ongoing 30-patient Phase 1 autoimmune basket. — Fierce Biotech
- Amgen is defending Tavneos as regulators in the U.S. and Europe push for withdrawal. — BioSpace
- Draft NICE guidance would block Lumakras reimbursement for new UK lung cancer patients. — Endpoints
- FDA criticized Lundbeck over deleted migraine webpages with allegedly inflated efficacy claims. — Endpoints
- HHS proposed a compensation mechanism for Covid-19 vaccine injury claims. — Endpoints
- Canada backed reimbursement for EMPAVELI in C3G and primary IC-MPGN. — PR
- ImmuCell posted preliminary Q2 product sales growth of 12%, with first-half sales up 21%. — PR
- PreTRM-guided care cut NICU admissions 22% in a PRIME subgroup analysis. — PR
- Roivant's strategy is tilting from spin-co creation toward commercial execution. — BioCentury
Deal Flow
|
BioBucks 2026 Deal Trackers • Updated weekly ⬇️
|
M&A / BD&L
- GSK is terminating its 2021 Alector neuro alliance (latozinemab, nivisnebart), unwinding a pact that carried a $700M upfront and up to ~$2.2B in total biobucks, after both assets failed. — Endpoints
VC / Private Financings
- No notable VC / private financings were identified in the last 24 hours.
IPOs / Follow-Ons
- No notable IPOs / follow-ons were identified in the last 24 hours.
Academic Corner - In idiopathic pulmonary fibrosis, inhaled treprostinil showed a smaller decline in forced vital capacity than placebo over 52 weeks. — NEJM
- A phase 1/2 trial reported a favorable 12-month safety profile for embryonic stem cell-derived dopaminergic cells in Parkinson's disease. — Nature Medicine
- HRS-4642 plus chemotherapy posted encouraging response rates in KRASG12D-mutant pancreatic cancer in a phase 1b/2 trial. — Nature Medicine
|
